Your browser doesn't support javascript.
loading
Patient preferences in the treatment of stage III/IV classic Hodgkin lymphoma: Results from the CONNECT cross-sectional survey.
Flora, Darcy R; Parsons, Susan K; Liu, Nicholas; Yu, Kristina S; Holmes, Katherine; Flores, Carlos; Fanale, Michelle A; Surinach, Andy; Byrd, Rachel; Evens, Andrew M.
Afiliación
  • Flora DR; Research Department, Gryt Health, Rochester, New York, USA.
  • Parsons SK; Department of Medicine and Pediatrics, Tufts University School of Medicine, Tufts Medical Center, Boston, Massachusetts, USA.
  • Liu N; Health Economics and Outcomes Research, Pfizer Inc., Bothell, Washington, USA.
  • Yu KS; Health Economics and Outcomes Research, Pfizer Inc., Bothell, Washington, USA.
  • Holmes K; Oncology, Ipsos Healthcare, New York, New York, USA.
  • Flores C; Genesis Research, Hoboken, New Jersey, USA.
  • Fanale MA; Health Economics and Outcomes Research, Pfizer Inc., Bothell, Washington, USA.
  • Surinach A; Genesis Research, Hoboken, New Jersey, USA.
  • Byrd R; Research Department, Gryt Health, Rochester, New York, USA.
  • Evens AM; Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
Br J Haematol ; 204(4): 1262-1270, 2024 Apr.
Article en En | MEDLINE | ID: mdl-38323849
ABSTRACT
We explored patient front-line treatment preferences in newly diagnosed stage III/IV classic Hodgkin lymphoma (cHL). The CONNECT patient survey, administered online from 30 December 2020 to 1 March 2021, examined preferences overall and by age at diagnosis in 182 adult patients diagnosed with stage III/IV cHL within the past 10 years in the United States. At diagnosis, patients' median age was 36 years; 66% of patients were younger (aged 16-41 years) and 34% older (aged 42-85 years). When asked about initial treatment goals, 74% of patients ranked cure as their first or second goal (86% younger vs. 52% older patients; p < 0.001). At diagnosis, 72% of patients preferred aggressive treatment, and 85% were willing to accept more short-term risks in exchange for a better-working therapy long term. For long-term risks, younger versus older patients were significantly more concerned about second cancers (p < 0.001) and fertility issues (p = 0.007), whereas older patients were more concerned about lung damage (p = 0.028) and infections (p < 0.001). Most patients (94%) reported having a caregiver at some point, but 99% of these patients retained some control of treatment decisions. Collectively, these survey results highlight patient treatment preferences and differences in treatment goals and long-term side effect concerns based on patient age.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin Tipo de estudio: Prevalence_studies / Risk_factors_studies Límite: Adult / Humans Idioma: En Revista: Br J Haematol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin Tipo de estudio: Prevalence_studies / Risk_factors_studies Límite: Adult / Humans Idioma: En Revista: Br J Haematol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido